Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Glutathione3 residuesECGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: GSH, L-Glutathione, Reduced Glutathione
Three amino acids. That is all glutathione is. Glutamate, cysteine, and glycine form a tripeptide that every cell in the body produces, and every cell depends on. Oral supplements barely register in bloodwork because proteases destroy roughly 90% of ingested GSH before it reaches circulation. Injectable glutathione bypasses that bottleneck entirely, delivering 100% bioavailability through subcutaneous, intramuscular, or IV routes. The skin brightening data is real but modest: one placebo-controlled RCT showed 37.5% of subjects responding after 12 sessions, and effects faded within six months of stopping. Athletes, longevity enthusiasts, and skin-focused users make up the core community, typically running 200 to 400 mg subcutaneous two to three times per week.
Every cell in the body produces glutathione, and every cell runs out of it under stress. GSH (L-glutathione, gamma-glutamylcysteinylglycine, CAS 70-18-8) is a tripeptide antioxidant that donates electrons to neutralize reactive oxygen species, then gets recycled by glutathione reductase using NADPH. That recycling loop is the reason it earned the "master antioxidant" label in biochemistry textbooks. Oral glutathione supplements have a bioavailability problem. GI proteases break down roughly 90% before absorption. A 2015 randomized controlled trial (Richie et al., n=54)[1] showed that 1,000 mg/day oral GSH raised body stores modestly over six months. Liposomal formulations do somewhat better (2019)[2]. But parenteral routes bypass digestion entirely and deliver near-100% bioavailability. Injectable GSH is used for three main goals: general antioxidant and detoxification support, exercise recovery, and skin brightening. The skin brightening pathway is specific; GSH inhibits tyrosinase and shifts melanin production from dark eumelanin toward lighter phaeomelanin. Zubair and colleagues tested this in a 2016 placebo-controlled RCT [3] using 1,200 mg IV twice per week for 12 sessions. Response rate was 37.5% in the treatment group versus 18.7% placebo. The effect was not permanent and faded at the six-month follow-up. No FDA-approved injectable glutathione product exists. All parenteral GSH comes from 503A or 503B compounding pharmacies, and sourcing quality matters. The FDA documented seven endotoxin poisoning hospitalizations from contaminated compounded glutathione in 2019. Community protocols for home use run 200 to 400 mg subcutaneous, two to three times per week, at a fraction of the risk profile that IV protocols carry.
Glutathione is a tripeptide of glutamate, cysteine, and glycine. The cysteine residue carries a sulfhydryl group that donates electrons directly to reactive oxygen species and free radicals. When GSH donates an electron, it becomes oxidized glutathione (GSSG). The enzyme glutathione reductase then regenerates GSH from GSSG, burning NADPH in the process. This redox cycle runs continuously in every cell. GSH also works as a cofactor. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid hydroperoxides. Glutathione S-transferase uses it in Phase II liver detoxification, conjugating xenobiotics and drug metabolites for excretion. These pathways handle acetaminophen metabolism, environmental toxin clearance, and heavy metal chelation. The skin brightening mechanism is distinct from general antioxidant activity. In melanocytes, GSH inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. It also shifts the melanogenesis pathway from eumelanin (dark pigment) toward phaeomelanin (lighter pigment). Watanabe and colleagues described this mechanism in a 2017 review [4]. The clinical result, when it occurs, is gradual skin lightening and tone evening. Plasma half-life of IV glutathione is roughly 10 minutes (Aebi et al., 1991)[5]. That sounds short, but intracellular GSH pools turn over on a two to three hour cycle. Parenteral delivery floods cells with substrate that sustains intracellular levels well beyond the plasma clearance window.
Antioxidant biochemistry is well-established; skin brightening has one placebo-controlled IV RCT showing ~37.5% response with results fading at 6 months; 2024–2025 systematic reviews conclude IV route risks outweigh modest brightening benefit.
Zubair et al. 2016 (PMID 27499402): 1,200 mg IV 2×/week × 12 sessions; 37.5% response vs. 18.7% placebo; effects faded by 6-month follow-up; 32% adverse event rate including one anaphylaxis case
Only one placebo-controlled IV skin-brightening RCT; 2024 systematic review (PMID 39444151) concluded IV route has "minimal efficacy and adverse effects"; no head-to-head SubQ vs. IV comparison; no RCT for antioxidant/energy indications; Parkinson's IV RCT (PMID 19230029, n=20) showed no significant UPDRS difference vs. placebo (P=0.32)
Widely used for energy, recovery, and skin brightening. Home SubQ at 200–400 mg 2–3×/week is the dominant protocol. Skin brightening outcomes described as inconsistent.
Community uses GSH broadly for energy, recovery, and skin goals; science validates antioxidant biochemistry but skin brightening evidence is limited (one RCT, 37.5% response, non-permanent). Recent 2024–2025 clinical reviews increasingly caution against IV route while community continues to use it. Community dosing (200–600 mg SubQ) is lower than clinical trial doses (1,200 mg IV) creating a protocol gap.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mg | 2x/week |
| Moderate | 400mg | 2x/week |
| Aggressive | 600mg | 3x/week |
A standard compounded vial is 1,500 mg. Add 3 mL bacteriostatic water and you get a concentration of 500 mg/mL. At that concentration, a 200 mg dose is 0.4 mL, which is 40 units on a U-100 insulin syringe. A 400 mg dose is 80 units. A 600 mg dose is 120 units, which exceeds a standard 1 mL syringe; split it into two 60-unit injections or use a 3 mL syringe with a 27G needle. GSH is light-sensitive. Store vials away from direct light, refrigerated at 2 to 8 degrees Celsius. Reconstituted vials stay good for about four weeks. The thing most beginners miss: oral NAC (N-acetylcysteine) between injection days supports endogenous GSH synthesis and is significantly cheaper. Stacking 600 to 1,200 mg oral NAC on off-days extends the benefit of your injection protocol without adding injection frequency. Vitamin C (1 to 2 g oral) directly regenerates oxidized GSSG back to reduced GSH through the ascorbate-glutathione redox cycle.
No desensitization documented, but periodic breaks are commonly recommended. Some users maintain indefinitely at lower frequency (1x/week) without cycling off.
Glutathione does not act on classical receptor targets (GPCRs, nuclear receptors) so pharmacological desensitization/tolerance does not apply. No published evidence supports cycling for efficacy preservation. Standard protocols use an 8–12 week loading phase followed by a lower-frequency maintenance phase (1×/week) for practical and cost reasons. Continuous use at maintenance frequency is practiced without established harm. Cycling rationale is logistical rather than pharmacological.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved energy, reduced brain fog, enhanced exercise recovery; effects sustained with maintenance dosing
Monitor: No blood work required at beginner doses. Monitor for injection site reactions and systemic allergic symptoms.
Clean the vial stopper and injection site with alcohol swabs. Let both air-dry for 10 seconds.
Draw 3 mL of bacteriostatic water into a syringe and inject it slowly into the 1,500 mg glutathione vial. Direct the stream against the glass wall, not the powder. Swirl gently until dissolved. Do not shake.
Using a U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle), draw your dose: 40 units for 200 mg, 80 units for 400 mg, or split 600 mg into two 60-unit draws.
Insert the needle at a 45 to 90 degree angle depending on body composition. Inject slowly over 30 to 60 seconds. Slower injection reduces discomfort.
Withdraw the needle and apply light pressure with a cotton ball. Do not rub.
Rotate injection sites each dose, maintaining at least 2 to 3 cm from your previous site to prevent lipohypertrophy.
Return the vial to the refrigerator (2 to 8 degrees Celsius) immediately. Protect from light. Discard after four weeks from reconstitution.
Post-workout or morning dosing is common, but GSH has no meal timing dependency. Stacking with 1 to 2 g oral vitamin C on injection days supports the redox recycling pathway.
Same mg dose as IM; Tmax ~30–60 min vs. 15–30 min IM
Use 27–31G insulin syringe. Inject into abdominal fat or upper thigh over 30–60 seconds to minimize discomfort. Rotate sites. Most practical and cost-effective home route.
Equivalent mg dose; faster absorption. Volumes >1 mL more comfortable via IM vs. SubQ.
Deltoid or ventrogluteal preferred. Used clinically for 200–600 mg doses. Larger-volume injections (1.2 mL at 600 mg with 500 mg/mL vial) better tolerated IM.
Immediate peak plasma concentration; doses 600–1,200 mg used vs. 200–600 mg SubQ/IM
Slow infusion over 15–30 minutes minimum: never rapid push. Rate-dependent side effects (flushing, nausea, chest tightness) resolve by slowing infusion. Anaphylaxis management must be immediately available.
~10× dose required for equivalent plasma effect; liposomal oral formulations modestly improve bioavailability
PMID 30002370 (2019) shows liposomal oral GSH increases whole blood glutathione vs. placebo, but does not match parenteral routes for acute elevation. Oral NAC (N-acetylcysteine) is a practical precursor bridge between injection sessions.
Not established for home protocols; device-assisted delivery required
IV PD protocol (1,400–2,800 mg 3×/week) failed primary endpoint in one RCT (PMID 19230029, n=20, P=0.32). Intranasal delivery is under investigation as a CNS-targeted alternative. No home protocol exists.
Mechanistic synergy: SIRT3 (NAD+-dependent) activates glutathione regeneration enzymes via NADPH pathway; GSH protects NAD+ pools by limiting PARP activation from oxidative DNA damage. Co-administered in longevity IV drip protocols.
NAD+ 250–500 mg IV over 2–4 hours; glutathione 200–600 mg IV push added at end of infusion
"Glow Stack": GHK-Cu drives collagen synthesis and tissue remodeling; GSH provides antioxidant protection and skin brightening. Complementary mechanisms with no documented adverse interaction.
Tissue repair stack: BPC-157 for gut/tissue healing combined with GSH for systemic antioxidant support. No documented interaction risk; used in recovery protocols.
Most universally stacked supplement with GSH. Ascorbate directly regenerates oxidized glutathione (GSSG→GSH) via the ascorbate-glutathione redox cycle. PMID 37946445 (2023): combined supplementation shows additive antioxidant effects vs. either alone in human athletes.
1–2 g oral vitamin C for home protocols; 2–25 g IV co-administered in same drip in clinic settings
IV glutathione directly neutralizes ozone through free radical scavenging; concurrent or same-session administration creates potentially harmful oxidative byproducts and defeats the therapeutic purpose of both treatments. PMID 40408806 (2025) explicitly warns against this combination.
Do not combineGlutathione potentiates hypotensive effects of nitroglycerin. Concurrent use may produce clinically significant blood pressure drop.
Pricing updated 2026-04-09
The most serious documented risk with injectable glutathione is endotoxin contamination from poorly compounded product. The FDA issued a 2019 safety alert after seven people were hospitalized with endotoxin poisoning from contaminated compounded glutathione traced to Letco Medical powder distributed to approximately 100 compounders across 30 states. Symptoms included fever, chills, hypotension, and tachycardia consistent with systemic inflammatory response syndrome (SIRS). This is a sourcing risk, not an inherent pharmacological risk, but it is the single most dangerous thing that can go wrong. Anaphylaxis is documented. The Zubair 2016 RCT [3] reported a 32% overall adverse event rate in the treatment group, including one case of anaphylaxis. Any setting administering IV glutathione must have epinephrine immediately available. For home subcutaneous users, keeping an EpiPen accessible during the first several injections is a reasonable precaution. A 2025 case report documented acute liver injury with SIRS requiring ICU admission after high-dose IV glutathione. This is a single case, but it reinforces the need for baseline liver function tests and repeat monitoring at six weeks for anyone using 600 mg or more at three times per week. Rate-dependent reactions are common with IV administration. Rapid IV push frequently produces flushing, nausea, and chest tightness. These are histamine-mediated and resolve completely by slowing the infusion to 15 to 30 minutes. They do not affect efficacy. Injection site reactions occur with subcutaneous dosing, particularly when users do not rotate sites. Lipohypertrophy (small lumps under the skin) develops with repeated injection at the same location. Rotating at least 2 to 3 cm from the prior site prevents this. Zinc depletion is a quieter concern. GSH chelates zinc, and chronic high-frequency dosing (three or more times per week for 8 to 12 weeks) may lower serum zinc enough to cause poor wound healing and altered taste. Baseline zinc testing and a recheck at 8 to 12 weeks catches this before symptoms appear. Sulfite sensitivity reactions have been reported in susceptible individuals. If you have a known sulfite allergy, discuss this with your prescriber before starting injectable GSH. Pregnancy and breastfeeding are contraindicated due to insufficient safety data for injectable glutathione. Asthma patients should exercise caution, as inhaled GSH has triggered bronchospasm in published reports. Organ transplant recipients on immunosuppressive therapy should avoid GSH given its immune-modulating properties, which could interfere with tacrolimus or cyclosporine. If you develop chills, fever, and low blood pressure after an injection, stop immediately and seek medical attention. That pattern could indicate endotoxin contamination and requires emergency evaluation.
Verify Glutathione dosing and safety with a second opinion
FDA issued a 2019 safety alert documenting 7 endotoxin poisoning hospitalizations from contaminated compounded glutathione (Letco Medical powder; ~100 compounders in 30 states affected). No FDA-approved injectable glutathione product exists. All sources are compounded 503A/503B or research-grade. January 2025 FDA compounding guidance tightened the 503A bulk substance pathway. Glutathione is classified as a dietary ingredient: its status on the FDA Category 1 bulk substances list for compounding remains unsettled.
| Test | When | Target |
|---|---|---|
| Liver function tests (ALT, AST, ALP, total bilirubin) | Baseline before starting high-dose protocols; repeat at 6 weeks if using ≥600 mg × 3×/week | ALT/AST within laboratory reference range; values >3× ULN warrant protocol pause |
| Serum zinc | Baseline; recheck at 8–12 weeks with high-frequency dosing (≥3×/week chronic use) | 70–120 mcg/dL |
| Blood pressure (sphygmomanometer) | Before and during IV infusion sessions | — |
Published IV skin-brightening RCT (Zubair 2016) reported liver enzyme elevations; 2025 case report documented acute liver injury with SIRS (ICU admission) after high-dose IV glutathione.
Chronic high-dose GSH use may deplete zinc; noted in product literature and community experience. GSH-zinc chelation documented.
IV glutathione may potentiate hypotensive effects, particularly when combined with nitroglycerin or in dehydrated patients. 2025 SIRS case presented with BP 50 mmHg. Rate-dependent hemodynamic effects with rapid IV push.
Most users notice increased energy and reduced brain fog within the first few sessions. IV administration shows effects faster than IM or SubQ. No visible skin changes yet.
Improved recovery from exercise, reduced hangover severity, and general well-being reported. Skin may begin to appear slightly brighter or more even-toned at higher doses.
Noticeable skin brightening in many users, especially at doses of 400-600mg 2-3x/week. Nail and hair quality may improve. Liver enzyme panels often show improvement if previously elevated.
Peak skin-lightening and antioxidant benefits with consistent use. Continued immune and detoxification support. Many users maintain a lower-frequency schedule for upkeep.
Week 1 to 2: Most users notice increased energy and reduced brain fog within the first few sessions. IV administration shows effects within hours; subcutaneous users typically feel changes within days. No visible skin changes at this stage. Injection site soreness and transient nausea (if IV is pushed too quickly) are the most common early side effects. Plasma GSH rises above baseline, and intracellular pools begin replenishing through cysteine delivery. Weeks 2 to 6: Exercise recovery improves noticeably. Hangover severity drops. Skin may begin appearing slightly brighter or more even at higher doses (400 to 600 mg range). GSH is actively inhibiting tyrosinase in melanocytes at this point, and the eumelanin-to-phaeomelanin shift starts at higher doses. Liver Phase II detoxification enzyme activity rises measurably. Injection site reactions may become more frequent with repeated subcutaneous dosing at the same location, so rotation matters. Weeks 6 to 12 (12 sessions): This is the response window for skin brightening. The Zubair 2016 RCT found that 37.5% of treatment subjects showed visible skin lightening versus 18.7% on placebo after 12 sessions. Nail and hair quality improvements are commonly reported alongside. Non-responders (roughly 63% of users) should honestly assess whether continuing is worthwhile. Liver enzyme elevations are possible at high IV doses; monitoring ALT and AST is important if running 600 mg or more IV three times per week. Post-cycle: Skin brightening effects fade within six months of stopping, per published follow-up data. Energy and recovery benefits typically drop off within two to four weeks. The majority of users shift to a maintenance schedule of once per week subcutaneous rather than stopping completely. Plasma GSH returns to individual baseline within days to weeks after discontinuation.
Plasma GSH elevated above baseline; intracellular GSH pools begin replenishment via cysteine delivery. No measurable melanin changes at this stage.
Increased energy, reduced brain fog, improved sleep quality most commonly reported. IV users may notice effects within hours of first session; SubQ users within days.
GSH inhibiting tyrosinase activity in melanocytes; eumelanin-to-phaeomelanin shift begins at higher doses. Liver phase II detoxification enzyme activity elevated.
Improved exercise recovery; skin tone may appear slightly brighter or more even. Hangover reduction commonly noted. Reduced post-workout muscle soreness.
Zubair 2016: 37.5% of treatment subjects show visible skin lightening vs. 18.7% placebo at 12 sessions. Melanin index reduction measurable in responders. Peak antioxidant enzyme activity.
Noticeable skin brightening and tone evening in responders; nail and hair quality improvements reported. Peak energy and recovery benefits. Non-responders should evaluate whether to continue.
Skin brightening effects fade within 6 months of discontinuation (Zubair 2016 follow-up). Plasma GSH returns to individual baseline within days to weeks.
Energy/recovery benefits fade 2–4 weeks after stopping. Skin tone gradually returns toward baseline. Majority of users shift to maintenance dosing (1×/week SubQ) rather than stopping completely.
Source: IV GSH is rapidly oxidized to GSSG with a plasma t½ of ~10 minutes; Aebi et al. 1991 PMID 1907548. Intracellular t½ is longer at 2-3 hours.
Loading the interactive decay curve.
Injectable glutathione has no FDA approval as a drug product. It is available exclusively through 503A and 503B compounding pharmacies with a prescription. The FDA classifies glutathione as a dietary ingredient, and its status on the Category 1 bulk substances list for compounding remains unsettled following January 2025 compounding guidance updates. The 2019 FDA safety alert targeted supplement-grade glutathione powder being used for compounding, not pharmaceutical-grade compounded product from accredited pharmacies. PCAB-accredited compounders such as Empower Pharmacy and Strive Pharmacy are cited most frequently in the community as reputable sources. Glutathione is not currently listed on the WADA prohibited substances list for athletes, but athletes in tested competitions should verify status with their governing body before use. No branded injectable glutathione product exists in the US market. Setria (Kyowa Hakko) is a branded ingredient used in oral supplements only, not an injectable product. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any injectable peptide protocol.
Peptide Schedule Research TeamReviewed Apr 202612 Citations
